Intercept Pharmaceuticals buy DomRuinart
Summary
This prediction ended on 22.03.18 with a price of €57.25. During the runtime of the prediction for Intercept Pharmaceuticals the price only changed by 0.36%. DomRuinart has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intercept Pharmaceuticals | - | - | - | - |
| iShares Core DAX® | 4.094% | 4.888% | 17.421% | 22.413% |
| iShares Nasdaq 100 | 1.424% | -0.445% | 37.618% | 58.203% |
| iShares Nikkei 225® | -1.572% | -4.911% | 12.951% | 7.961% |
| iShares S&P 500 | 1.822% | 0.776% | 29.182% | 49.914% |
Comments by DomRuinart for this prediction
In the thread Intercept Pharmaceuticals diskutieren
Überdosis
Okay, wenn man sich nicht an die Dosieruingsanweisungen hält, ist Ocaliva gefährlich...ich halte die Kursreaktion auf diese Nachricht für zu heftig. Ich denke, RBC Capital Market sieht die Sache realistisch:
...RBC Capital Market analysts have a different take, Reuters
said. The concerns about Ocaliva were already known and included on the
drug’s prescribing label. More so, the patients who were affected by
the problems cited by the FDA represent less than 5 percent of the
overall PBC population. That means it would be likely any negative
commercial impact would be too serious, the analysts said, according to Reuters. Approximately 15,000 prescriptions for Ocaliva have been written since it was approved, Bloomberg noted.
Quelle: biospace.com
Ich denke man kann den Rücksetzer für einen Einstieg nutzen.